Harvard Business Review

OCTOBER 23, 2014

Energy, agriculture, insurance, retail, human resources — no industry is unaffected. That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. Or lenders’ enhanced abilities to gauge credit risk. They’re also sharing risk. But not for long.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

JANUARY 5, 2018

For more than a decade, leading human resource strategists have hit on a recurring theme: You want your star players working in the roles that matter most to the business. Although long ignored, these middle management positions have become increasingly recognized as critical to executing a company’s strategy.

McKinsey 8

McKinsey Human Resources Reputation Brand 8

Harvard Business Review

NOVEMBER 3, 2014

Once upon a time, executive coaching was viewed as a remedial intervention for executives and managers who needed to be “fixed” in some way. Managers were not expected to be particularly involved in the coachee’s exploration or journey. Coaching was even sometimes viewed as “outsourcing” the management of a difficult employee.

Participative 8

Participative 360-Degree Feedback Executive Coaching How To 8

Harvard Business Review

NOVEMBER 3, 2014

Once upon a time, executive coaching was viewed as a remedial intervention for executives and managers who needed to be “fixed” in some way. Managers were not expected to be particularly involved in the coachee’s exploration or journey. Coaching was even sometimes viewed as “outsourcing” the management of a difficult employee.

Participative 8

Participative 360-Degree Feedback Executive Coaching How To 8

Harvard Business Review

MAY 29, 2013

Helping determine their professional development and best interests becomes a welter of conflicting interests. Well-intentioned top management interventions — sincere efforts to help produce an better balanced employee — might have snuffed out the entrepreneurial essence that made Jobs one of the world''s greatest innovators.

Competitive Advantage 9

Competitive Advantage Ethics Human Resources Pharmaceuticals 9

Harvard Business Review

NOVEMBER 20, 2015

One result is that they keep their cards close to their chests about what they are looking for (at first), while expecting you to reveal everything – your finances, pricing, ownership, human resources, production processes, quality assurance, customer service procedures, KPIs, and existing customers.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

OCTOBER 24, 2014

Here are some of the challenges that I’ve observed: Product management. In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. Human resources.

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. This will not only challenge tax departments’ current calculations, but will also put increasing pressure on legal departments wrestling with IP asset and risk management. trillion in inventories held by U.S.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

OCTOBER 27, 2015

At UCB, a medium-sized pharmaceutical company headquartered in Belgium, Heresh Rezavandi and his managers Michelle Maddix-Sovero are leading a young strategic intelligence function that’s part of the strategic marketing practice. This helps keep the team’s efforts focused. ” Get business leaders involved. .”

Marketing 8

Marketing Competitive Intelligence Porter How To 8

Harvard Business Review

MARCH 14, 2017

When one of us (Vivek) and his team launched Roivant Sciences in 2014 and began developing treatments for Alzheimer’s disease — they were determined to learn from the pharma industry’s innovation issues and build a more sustainable innovation engine. Roivant’s first response was to address misaligned incentives.

Innovation 10

Innovation Company Incentives Industry 10